These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29228077)

  • 1. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?
    Prasad V
    JAMA Pediatr; 2018 Feb; 172(2):123-125. PubMed ID: 29228077
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy.
    Richardson RC
    JAMA Pediatr; 2018 Jul; 172(7):701. PubMed ID: 29801053
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply.
    Prasad V
    JAMA Pediatr; 2018 Jul; 172(7):701-702. PubMed ID: 29800980
    [No Abstract]   [Full Text] [Related]  

  • 4. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nusinersen in the treatment of spinal muscular atrophy].
    Sinkó G; Kiss Z; Kalman B
    Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
    Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
    J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
    Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
    J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
    Gidaro T; Servais L
    Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen for spinal muscular atrophy: Not just for babies?
    Ciafaloni E; Russman BS
    Neurology; 2019 May; 92(21):985-986. PubMed ID: 31019098
    [No Abstract]   [Full Text] [Related]  

  • 13. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
    Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
    Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
    [No Abstract]   [Full Text] [Related]  

  • 14. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
    Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
    Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
    Aartsma-Rus A
    Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
    [No Abstract]   [Full Text] [Related]  

  • 16. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
    Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
    JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen in adults with spinal muscular atrophy: new challenges.
    Mercuri E; Sansone V
    Lancet Neurol; 2020 Apr; 19(4):283-284. PubMed ID: 32199087
    [No Abstract]   [Full Text] [Related]  

  • 18. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.
    Corey DR
    Nat Neurosci; 2017 Apr; 20(4):497-499. PubMed ID: 28192393
    [No Abstract]   [Full Text] [Related]  

  • 19. Nusinersen Use in Spinal Muscular Atrophy.
    Pediatrics; 2019 Jan; 143(1):. PubMed ID: 30584063
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
    Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
    Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.